Company Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Abbisko Cayman Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:38:22 29/04/2024 pm IST			5-day change	1st Jan Change
3.32 ^HKD	+1.22%		+10.30%	-9.04%

25/04	Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation	MT
24/04	Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	CI

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâs products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Number of employees: 258

HKD in Million	2022	Weight	2023	Weight	Delta
Innovative Medicines 100.0 %	0	nan %	21	100.0 %	-

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	0	nan %	21	100.0 %	-

Managers	Title	Age	Since
Zhui Chen FOU	Founder	49	12/16/12
Yao Chang Xu CEO	Chief Executive Officer	67	12/16/12
Hong Ping Yu FOU	Founder	56	12/16/12
Zi Dong Zhang DFI	Director of Finance/CFO	43	16/22/16
Jing Ji CTO	Chief Tech/Sci/R&D Officer	54	01/21/01
Hui Min Tian COO	Chief Operating Officer	-	-
Jia Feng HRO	Human Resources Officer	-	-
Yong Yi Li LAW	General Counsel	49	01/21/01
Ke Wei Xie PRN	Corporate Officer/Principal	63	14/20/14
Zhen Zhang PRN	Corporate Officer/Principal	50	01/21/01

Members of the board	Title	Age	Since
Hong Bin Sun BRD	Director/Board Member	48	30/21/30
Piao Yang Sun BRD	Director/Board Member	65	30/21/30
Hong Ping Yu FOU	Founder	56	12/16/12
Zhui Chen FOU	Founder	49	12/16/12
Yao Chang Xu CEO	Chief Executive Officer	67	12/16/12
Yan Min Tang BRD	Director/Board Member	51	10/21/10
Lei Wang BRD	Director/Board Member	51	30/21/30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	701,774,350	529,424,960 ( 75.44 %)	0	75.44 %

Name	Equities	%	Valuation
Yao Chang Xu 11.86 %	83,297,074	11.86 %	31 M $
LAV Management Co., Ltd. 10.02 %	70,361,790	10.02 %	26 M $
Qiming Venture Partners Ltd. 6.921 %	48,596,400	6.921 %	18 M $
Temasek Holdings Pte Ltd. (Investment Management) 3.319 %	23,307,460	3.319 %	9 M $
Hong Ping Yu 2.816 %	19,772,894	2.816 %	7 M $
Zhui Chen 2.633 %	18,490,051	2.633 %	7 M $
UBS Asset Management (Hong Kong) Ltd. 1.490 %	10,462,000	1.490 %	4 M $
Fidelity Management & Research (Hong Kong) Ltd. 0.6831 %	4,797,000	0.6831 %	2 M $
HuaAn Fund Management Co., Ltd. 0.0790 %	555,000	0.0790 %	204 229 $

Abbisko Cayman Ltd.

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park

, Shanghai

+86 21 6891 2098

http://www.abbisko.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.073 CNY

Average target price

7.572 CNY

Spread / Average Target

+146.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ABBISKO CAYMAN LIMITED	-9.04%	245M
VERTEX PHARMACEUTICALS INCORPORATED	-2.58%	103B
REGENERON PHARMACEUTICALS, INC.	+1.81%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.75%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.23%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.81%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.08%	12.17B

Bio Therapeutic Drugs